3045-32-7

Basic information

• Product Name: 2-(2-hydroxypropan-2-yl)phenol
• Synonyms: 2-(2-hydroxypropan-2-yl)phenol;o-Hydroxy-α,α-diMethylbenzyl Alcohol;2-(2-HYDROXYPROPAN-2-YL)PHENOL(WX191756)
• CAS NO: 3045-32-7
• Molecular Formula: C₉H₁₂O₂
• Molecular Weight: 152.19038
• Mol File: 3045-32-7.mol
• Article Data: 20

Chemical Properties

• Melting Point: 41-44 °C
• Boiling Point: 252.7±7.0 °C(Predicted)
• Appearance: /
• Density: 1.122±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Methanol (Slightly)
• PKA: 10.15±0.35(Predicted)
• CAS DataBase Reference: 2-(2-hydroxypropan-2-yl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-hydroxypropan-2-yl)phenol(3045-32-7)
• EPA Substance Registry System: 2-(2-hydroxypropan-2-yl)phenol(3045-32-7)

Safety Data

• Hazardous Substances Data: 3045-32-7(Hazardous Substances Data)

Usage

Uses

o-Hydroxy-α,α-dimethylbenzyl Alcohol is an intermediate in the synthesis of 2,4’-Bisphenol A (B519490), an derivative used for the preparation of low-molecular-weight epoxy resins.

Upstream product

• 917-64-6 methyl magnesium iodide 
• 60-29-7 diethyl ether 
• 27701-23-1 methyl 2-(methoxymethyloxy)benzoate 
• 10277-93-7 2-isopropenylphenol 
• 75-16-1 methylmagnesium bromide 
• 118-93-4 o-hydroxyacetophenone 
• 74-88-4 methyl iodide 
• 676-58-4 methylmagnesium chloride 
• 77023-05-3 1-<((trimethylsilyl)oxy)methyl>-1,2-benzene oxide 
• 77023-06-4 1-<((trimethylsilyl)oxy)methyl>-1,2-oxido-4-cyclohexene 
• 77023-23-5 (3,4-Dibromo-7-oxa-bicyclo[4.1.0]hept-1-ylmethoxy)-trimethyl-silane 
• 77023-02-0 1-(hydroxymethyl)-1,2-oxido-4-cyclohexene 
• 32937-33-0 1-(hydroxymethyl)cyclohexa-1,4-diene 
• 119-36-8 methyl salicylate 

Downstream Products

• 82466-10-2 2,4,4-Trimethyl-4H-benzo[1,3]dioxine 
• 1196734-02-7 C₁₂H₁₈O₃ 
• 1196734-03-8 C₂₀H₂₁NO₄ 
• 870553-71-2 C₁₁H₁₆O₃ 
• 5026-12-0 2-(2-hydroxyphenyl)-2,4,4-trimethylchroman 
• 1632131-06-6 3-acetyl-2,4,4-trimethyl-4H-chromene 
• 1429879-02-6 2-[2-(2-azido-2-{3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}ethoxy)phenyl]propan-2-ol 
• 1452807-42-9 C₂₉H₂₈ClNO₅S 
• 1429879-01-5 2-[2-(2-{3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}-2-hydroxyethoxy)phenyl]propan-2-ol 
• 39477-82-2 2-(2-hydroxyphenyl)-2-methoxypropane 
• 38865-54-2 <1-(2-Hydroxyphenyl)-1-methylethyl>-(2-isopropenylphenyl)-ether 
• 10278-02-1 2-(2-methoxyphenyl)propene 
• 137408-19-6 2-(2-Isopropenyl-phenoxy)-propionic acid ethyl ester 
• 137408-17-4 2-(2-isopropenylphenoxy)propanoic acid 

Relevant articles and documents

Regioselective reductive openings of acetals; mechanistic details and synthesis of fluorescently labeled compounds

Regioselective reductive openings of mixed phenolic-benzylic acetals, using BH3·NMe3-AlCl3, was investigated, and a mechanism where the outcome is directed by the electrostatic potential of the two oxygen atoms is presente

Multicomponent Condensation Reactions via ortho-Quinone Methides

Iron(III) salts promote the condensation of aldehydes or acetals with electron-rich phenols to generate ortho-quinone methides that undergo Diels - Alder condensations with alkenes. The reaction sequence occurs in a single vessel to afford benzopyrans in up to 95% yield. The reaction was discovered while investigating a two-component strategy using 2-(hydroxy(phenyl)methyl)phenols to access the desired ortho-quinone methide in a Diels - Alder condensation. The two-component condensation also afforded the corresponding benzopyran products in yields up to 97%. Taken together, the two- and three-component strategies using ortho-quinone methide intermediates provide efficient access to benzopyrans in good yields and selectivities.

CYSTEINYL LEUKOTRIENE ANTAGONISTS

The present invention relates to novel cysteinyl leukotriene (specifically LTD4) antagonists, mainly to quinolin, quinoxaline or benz[c]thiazole derivatives represented by the general formula (I), or the pharmaceutically acceptable salt thereof, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to cysteinyl leukotriene, in mammals, more specially in humans.